Gilead Unveils Results From HIV Phase 1b Trial
March 10 2020 - 3:37PM
Dow Jones News
By Michael Dabaie
Gilead Sciences Inc. unveiled results from a Phase 1b trial
evaluating its vesatolimod as part of a human immunodeficiency
virus cure research program.
These findings mark the first clinical data showing toll-like
receptor 7 stimulation by vesatolimod is associated with a modestly
increased time to viral rebound compared to placebo, as well as
enhanced immune function and decreased levels of intact HIV DNA,
Gilead said.
"The effects are modest, and no one came close to any definition
of a cure, but the data suggests real progress might be made when
the drug is used in combination with other approaches," said
principal investigator Steven Deeks, professor of medicine at the
University of California, San Francisco.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 10, 2020 15:22 ET (19:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024